-
Sorrento Gets DARPA Contract For Up To $34M To Develop Neutralizing Antibodies For COVID-19
2020 Nov 27, 10:10am | 333Read More...Sorrento Therapeutics Inc (NASDAQ: SRNE) shares, which have been given to much volatility, are rallying sharply Friday. What Happened: SmartPharm Therapeutics, a subsidiary of Sorrento, announced a contract award by the Defense Advanced Research Projects Agency for developing a gene-encoded...
-
Here's How Much Investing $1,000 In Major Coronavirus Vaccine Developers Before Their Announcements Would Fetch
2020 Nov 27, 9:21am | 993Read More...Stocks with a COVID-19 vaccine angle have made significant gains on developmental milestones, and in some cases have shown what is arguably irrational exuberance. Irrational Exuberance Or Thought-Out Strategy? The rally seen in vaccine developers has come despite skepticism regarding the...
-
Moderna Finalizes European Supply Deal For Up To 160M COVID-19 Vaccine Doses
2020 Nov 25, 2:29pm | 370Read More...Moderna Inc (NASDAQ: MRNA) shares were advancing Wednesday after the announcement of a vaccine supply deal with the European Commission. What Happened: The Cambridge, Massachusetts-based biopharma said the European Commission has approved an agreement for the company to supply 80 million...
-
How MindMed Uses Tech To Innovate, Deploy Psychedelic Mental Health Therapies
2020 Nov 25, 8:11am | 990Read More...In an exclusive to Benzinga, Mind Medicine (MindMed) Inc (OTC: MMEDF), a leading medicine biotech company in psychedelics, on Tuesday revealed the introduction of a division known as Albert, to help research and develop an integrated platform for delivering psychedelic medicines, experiential...
-
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
2020 Nov 25, 7:35am | 1359Read More...Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24) AbbVie Inc (NYSE: ABBV) Affimed NV (NASDAQ: AFMD) Apellis Pharmaceuticals Inc (NASDAQ: APLS) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) C4...
-
6.4M Pfizer COVID-19 Vaccine Doses To Be Distributed Across US Within 24 Hours Of FDA Approval: WaPo
2020 Nov 25, 1:18am | 387Read More...Over six million doses of Pfizer Inc’s (NYSE: PFE) COVID-19 vaccine could be distributed within 24 hours of it being given the go-ahead by the United States Food And Drug Administration, The Washington Post reported Tuesday. What Happened: The vaccine’s 6.4 million doses would be...
-
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
2020 Nov 24, 8:12am | 2186Read More...Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23) AbbVie Inc (NYSE: ABBV) Affimed NV (NASDAQ: AFMD) ALX Oncology Holdings Inc (NASDAQ: ALXO) Apellis Pharmaceuticals Inc (NASDAQ: APLS) Atara...
-
Novartis Kicks Off $2.5B Share Buyback Program On Strong Pipeline Growth
2020 Nov 24, 7:13am | 329Read More...On Tuesday, Swiss biopharma company Novartis AG (NYSE: NVS) announced a $2.5 billion share buyback program. The management also exhibited a heightened confidence level in its sales projections based on the current pipeline of products under development. What Happened: The...
-
Moderna Hopes To Roll Out COVID-19 Vaccine For Children By Mid-Next Year
2020 Nov 24, 1:07am | 449Read More...Moderna Inc (NASDAQ: MRNA) Chief Medical Officer Tal Zaks said that the drugmaker’s COVID-19 vaccine would be available for children by mid-2021, Axios reported Monday. What Happened: Zaks told Axios On HBO in an interview that he hopes that the vaccine for children would be available by...
-
AstraZeneca Analyst Flags Lack Of Details In Interim COVID-19 Vaccine Data
2020 Nov 23, 2:21pm | 686Read More...AstraZeneca plc (NASDAQ: AZN) announced Monday interim Phase 3 data for its coronavirus vaccine candidate AZD1222 from studies conducted in the U.K. and Brazil, showing efficacy ranging between 62% and 90%. The AstraZeneca Analysts: SVB Leerink analyst Geoffrey Porges has an Outperform rating on...
-
Merck To Buy Late-Stage COVID-19 Treatment Company OncoImmune For $425M In Cash
2020 Nov 23, 11:19am | 497Read More...Merck & Co., Inc. (NYSE: MRK), which has been lagging behind some of its large-pharma peers in COVID-19 treatment and vaccine development, announced the purchase Monday of a private company with a late-stage COVID-19 treatment candidate. What Happened: Merck said it has executed a...
-
FDA Approves Eiger Biopharma's Progeria Treatment: What Investors Should Know
2020 Nov 23, 10:45am | 393Read More...The FDA approved Eiger Biopharmaceuticals Inc (NASDAQ: EIGR)'s lonfarnib Friday for the treatment of Hutchinson-Gilford Progeria Syndrome, commonly referred to as progeria, as well as processing-deficient progeroid laminopathies. The Palo Alto, California-based company focuses on...
-
AstraZeneca COVID-19 Vaccine Shows Up To 90% Efficacy In Advanced Trials
2020 Nov 23, 3:11am | 494Read More...AstraZeneca Plc (NYSE: AZN) and Oxford University’s COVID-19 vaccine prevented 70% of the inoculated trial participants from developing COVID-19, early analysis of trial data indicates. What Happened: The results were based on data gathered from two different dosing regimens. One dosing...
-
Bill Gates Says AstraZeneca, Johnson & Johnson, Novavax COVID-19 Vaccines All Likely To Prove 'Very Efficacious And Safe' By February
2020 Nov 23, 2:44am | 529Read More...Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates expressed optimism on the efficacy of COVID-19 vaccines made by various drugmakers in an interview with CNN on Sunday. What Happened: The billionaire told CNN’s Fareed Zakaria that while vaccines from Pfizer Inc (NYSE: PFE) and...
-
Regeneron's COVID Treatment Gets Emergency FDA Approval
2020 Nov 22, 9:07am | 216Read More...The U.S. Food and Drug Administration has issued emergency use authorization for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail. Why It Matters: The two antibodies in the treatment, casirivimab and imdevimab, were shown to reduce COVID-19-related hospital trips within...
